OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ET
Company Participants
Gabby Woody – Executive Assistant, HR Coordinator
Josh Riggs – President and CEO
Andrea James – CFO
Ekke Schutz – CSO
Conference Call Participants
Mark Massaro – BTIG
Mike Matson – Needham
Mason Carrico – Stephens
Gabby Woody
Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Attendees may also type questions into the Q&A.
Before turning the call over to Josh Riggs, I’d like to go over our safe harbor. The company will make projections and forward-looking statements regarding future events. Any statements that are not historical facts are forward-looking statements. These statements are made pursuant to and within the meaning of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. We encourage you to review the company’s SEC filings, including the company’s most recent Form 10-K and subsequent Forms 10-Q, which identify risks and uncertainties that may cause future actual results or events to differ materially. Please note that the forward-looking statements made during today’s call speak only to the date they are made and Oncocyte undertakes no obligation to update them.
And with that, I would like to now turn the call over to Josh Riggs.
Josh Riggs
Thanks, Gabby. Hello, everyone. Thanks for joining. We’ve gotten a lot done since our update in November. It’s great to be closer than ever to having our clinical assay on market. While we detail our 2024 highlights in the shareholder letter, I’ll just briefly recap them here. We launched GraftAssure, which is our research use-only kidney transplant test, with some of the leading transplant centers in the world, proving that we could design, develop, and
#OncoCyte #Corporation #OCX #Earnings #Call #Transcript